Zarah ChoudharyZurich Corporate Risk has introduced its new Precision CancerCare service for both new and reviewing customers.
Provided in partnership with Further, a specialist in niche health service solutions, the service offers access to comprehensive genetic testing using the latest tumour profiling technology and expert medical panels.
Cancer is the leading cause of claim for Zurich Corporate Risk, and ensuring customers and their employees have the best support is a primary focus.
Precision CancerCare is available for all advanced and complex cancers, providing customised treatment plans based on the molecular drivers of the tumour.
This approach aims to improve patient outcomes, reduce negative side effects of unnecessary treatments, and enhance overall quality of life.
The service also delivers a clinical report with personalised guidance on treatment options and advice.
Key features include testing in world-leading laboratories, expert-reviewed results, navigation assistance on clinical trials, and coordination with the employee’s treating clinician.
If a hereditary mutation is identified, children are offered testing and counselling.
Zurich Corporate Risk has also introduced a new second medical opinion service, also provided by Further, offering customers access to an independent evaluation of a diagnosis, treatment plan, or medical condition.
This service supported individuals and their families in understanding their medical conditions and making informed health decisions.
It includes an in-depth review by medical experts, access to global specialists, a full clinical report with recommendations, a dedicated Case Navigator, and access to Precision CancerCare through the Second Medical Opinion+ service.
Cindy Warden, head of Zurich Corporate Risk, said: “Zurich is delighted to partner with Further Group to significantly enhance the value-added services available to our group risk customers.
“Precision CancerCare is a leading edge clinical capability and has huge potential to improve outcomes for individuals with a serious cancer diagnosis.”
Frank Ahedo, chief executive officer at Further, said: “We are thrilled to strengthen our partnership with Zurich Insurance in the UK.
“We have truly found a partner that shares our passion for innovation and our ambition to make a meaningful impact by supporting those facing critical healthcare challenges.”
